逆转肽有效抑制实验性自身免疫性甲状腺炎中的甲状腺抗原呈递:通往甲状腺自身免疫免疫治疗之路
本研究设计针对HLA-DRβ1-Arg74的逆转D-氨基酸肽RT-15和VT-15,体外阻断肽结合与T细胞活化,并在人源化NOD-DR3小鼠实验性自身免疫性甲状腺炎中阻断甲状腺球蛋白诱导的T细胞活化,为携带DRβ1-Arg74等位基因的自身免疫性甲状腺疾病患者提供个体化治疗思路。
要点
- RT-15和VT-15在体外阻断肽与重组HLA-DRβ1-Arg74结合及T细胞活化。
- RT-15和VT-15在实验性自身免疫性甲状腺炎人源化NOD-DR3小鼠中阻断甲状腺球蛋白诱导的体内T细胞活化。
- 该抗原特异性策略为携带DRβ1-Arg74的自身免疫性甲状腺疾病患者提供个体化治疗可能。
核心结论
- 发现两种逆转D-氨基酸肽RT-15和VT-15可阻断甲状腺球蛋白肽与HLA-DRβ1-Arg74结合及其向T细胞呈递。
- 这些发现为携带DRβ1-Arg74等位基因的自身免疫性甲状腺疾病患者奠定了个体化治疗基础。
- 该抗原特异性治疗策略可能扩展至其他自身免疫性疾病。
研究设计与样本
- 研究通过计算方法和分子动力学模拟设计逆转D-氨基酸肽,并在体外及人源化NOD-DR3小鼠实验性自身免疫性甲状腺炎模型中验证。
主要发现
- RT-15和VT-15阻断肽与重组HLA-DRβ1-Arg74分子结合,并阻断体外T细胞活化。
- RT-15和VT-15在甲状腺球蛋白诱导的实验性自身免疫性甲状腺炎人源化NOD-DR3小鼠中阻断体内T细胞活化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Autoimmune thyroid diseases (AITD) represent the most common autoimmune diseases. However, current therapies focus on relieving the symptoms instead of curing AITD, and new therapies to reverse the autoimmune attack on the thyroid are needed. HLA-DRβ1-Arg74 is the key HLA class II allele that triggers AITD by presenting pathogenic thyroglobulin (Tg) peptides that activate thyroid self-reactive T cells. We hypothesized that blocking the presentation of Tg peptides to T cells within the HLA-DRβ1-Arg74 peptide binding cleft could reverse the autoimmune response to the thyroid in AITD. Methods: The approach we used to block Tg peptide presentation within HLA-DRβ1-Arg74 is to design retro-inverso D-amino acid (RID) peptides that have high affinity to the HLA-DRβ1-Arg74 peptide binding pocket. Results: By using computational approaches and molecular dynamics simulations, we designed two RID peptides, RT-15 and VT-15, that blocked peptide binding to recombinant HLA-DRβ1-Arg74 molecule, as well as T cell activation in vitro. Furthermore, RT-15 and VT-15 blocked in vivo T cell activation by thyroglobulin in humanized NOD-DR3 mice induced with experimental autoimmune thyroiditis. Conclusions: In summary, we discovered two RID peptides that block thyroglobulin peptide binding to HLA-DRβ1-Arg74 and their presentation to T cells in AITD. These findings set the stage for a personalized medicine therapeutic approach for AITD patients who carry the DRβ1-Arg74 allele. This antigen-specific therapeutic strategy can potentially be extended to other autoimmune diseases.
引用
- Li CW, Osman R, Menconi F, et al. Effective Inhibition of Thyroid Antigen Presentation Using Retro-Inverso Peptides in Experimental Autoimmune Thyroiditis: A Pathway Toward Immune Therapies of Thyroid Autoimmunity. Thyroid. 2023. PMID: 36762945. doi:10.1089/thy.2022.0511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。